FGF21 and obesity due to melanocortin 4 receptor deficiency: Treatment with FGF21 ameliorates metabolic disorders such as insulin resistance, dyslipidemia and obesity in mice [6, 19], and treatment of human volunteers with FGF21 analogs has shown beneficial effects on metabolic disorders ranging from obesity and type 2 diabetes to non-alcoholic liver diseases [31].